Details of the Drug

General Information of Drug (ID: DM62UG5)

Drug Name
Vemurafenib
Synonyms PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
L01EC01: Vemurafenib
L01EC: B-Raf serine-threonine kinase (BRAF) inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 489.9
Logarithm of the Partition Coefficient (xlogp) 5
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 601 mgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 62 mg/L [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The total body clearance of drug is 31 L/day [4]
Elimination
Analysis showed that 94% of administered Vemurafenib is excreted via feces and 1% is excreted by urine [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 57 hours [4]
Metabolism
The drug is metabolized via the CYP3A4 and the metabolites make up 5% of the components in plasma [4]
Vd
The volume of distribution (Vd) of drug is 106 L [4]
Chemical Identifiers
Formula
C23H18ClF2N3O3S
IUPAC Name
N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
Canonical SMILES
CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
InChI
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
InChIKey
GPXBXXGIAQBQNI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
42611257
ChEBI ID
CHEBI:63637
CAS Number
918504-65-1
UNII
207SMY3FQT
DrugBank ID
DB08881
TTD ID
D0Y9EW
VARIDT ID
DR00711
INTEDE ID
DR1677
ACDINA ID
D00723
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase B-raf (BRAF) TTWCGQT BRAF_HUMAN Modulator [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [6]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5,6-dihydroxyindole-2-carboxylic acid oxidase OTRK49R4 TYRP1_HUMAN Gene/Protein Processing [9]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [10]
CD70 antigen (CD70) OTHB2AL1 CD70_HUMAN Gene/Protein Processing [11]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Gene/Protein Processing [12]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Gene/Protein Processing [12]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Drug Response [13]
GTPase NRas (NRAS) OTVQ1DG3 RASN_HUMAN Drug Response [13]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Drug Response [14]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Gene/Protein Processing [10]
Melanocyte protein PMEL (PMEL) OTCDDHHM PMEL_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serine/threonine-protein kinase B-raf (BRAF) DTT BRAF 3.00E-01 0.1 0.2
P-glycoprotein 1 (ABCB1) DTP P-GP 9.48E-02 1.45E-01 2.92E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 7.57E-04 7.55E-03 3.42E-02
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 5.98E-03 9.85E-03 5.46E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.75E-01 3.78E-02 1.44E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 138 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 7.2465 9.8968 4.1149 1.2003
JK1 CTRP2 8.7067 10.826 4.3651 0.1426
JM1 CTRP2 4.495 6.3874 3.8738 6.0946
EoL-1 CTRP2 1.042 2.1004 1.0418 26.6654
LP-1 CTRP2 1.6874 3.2733 1.6737 22.4108
697 CTRP2 1.9656 4.1423 1.8808 20.7996
EB1 CTRP2 2.1246 4.8736 1.9029 20.2226
Pfeiffer CTRP2 2.8897 4.5803 2.8014 14.6573
KMS-34 CTRP2 3.1429 4.2683 3.1185 12.7502
KMS-20 CTRP2 3.2135 4.7078 3.1271 12.4949
L-428 CTRP2 3.2249 5.8539 2.791 13.6972
NU-DUL-1 CTRP2 3.5001 5.288 3.2868 11.0454
GA-10 CTRP2 3.5303 5.3979 3.2836 10.9685
DB CTRP2 3.5442 6.0636 3.0488 11.8215
KMS-12-BM CTRP2 3.5981 5.5121 3.3175 10.6451
Mono-Mac-1 CTRP2 3.7246 5.2637 3.5387 9.453
F-36P CTRP2 3.851 5.6616 3.5335 9.1095
L-540 CTRP2 3.8621 4.6392 3.838 7.9584
MOTN-1 CTRP2 3.8914 6.4194 3.258 10.0782
MOLT-16 CTRP2 3.9251 5.3872 3.7147 8.213
RS4;11 CTRP2 4.1087 6.8597 3.2743 9.4681
U-937 CTRP2 4.1406 6.2954 3.5665 8.2098
SUP-M2 CTRP2 4.1524 5.1508 4.04 6.3401
CA46 CTRP2 4.2041 6.4589 3.5552 8.0958
TALL-1 [Human adult T-ALL] CTRP2 4.2884 5.9617 3.866 6.6362
OCI-AML-3 CTRP2 4.2916 5.1311 4.1976 5.3477
JJN-3 CTRP2 4.3577 5.2828 4.2186 5.0761
Daudi CTRP2 4.3851 5.9093 3.9878 5.9026
THP-1 CTRP2 4.3899 5.651 4.1062 5.4207
Namalwa CTRP2 4.4017 6.1861 3.8777 6.3043
KYO-1 CTRP2 4.4182 6.3122 3.8349 6.4372
A3/Kawakami CTRP2 4.4599 5.1501 4.3748 4.1968
SUP-T11 CTRP2 4.5383 5.3164 4.3997 3.8785
HuNS1 CTRP2 4.5654 16.7804 -1.2274 24.6838
KMS-18 CTRP2 4.5823 6.4894 3.9081 5.75
DEL CTRP2 4.6312 4.9551 4.6144 2.8103
NU-DHL-1 CTRP2 4.6621 6.8017 3.8298 5.8943
KMS-11 CTRP2 4.6789 5.7609 4.3495 3.7121
MOLT-3 CTRP2 4.7069 5.2095 4.6207 2.5624
SET-2 CTRP2 4.7625 5.2709 4.6549 2.2777
OPM-2 CTRP2 4.7847 5.7703 4.4475 3.0596
OCI-AML-5 CTRP2 5.0048 5.7203 4.6729 1.6398
HD-MY-Z CTRP2 5.1188 6.6539 4.3008 2.9849
HPB-ALL CTRP2 5.298 6.58 4.4763 1.9405
Kasumi-2 CTRP2 5.4767 7.7617 4.027 3.5109
RCH-ACV CTRP2 5.5639 7.9922 3.9779 3.5742
U266B1 CTRP2 5.6077 9.5609 3.2367 6.5761
Karpas-620 CTRP2 5.6267 7.2153 4.3974 1.7795
AML-193 CTRP2 5.6639 8.5259 3.789 4.1945
REC-1 CTRP2 5.7878 8.3981 3.9394 3.3908
MC116 CTRP2 5.8424 11.5046 2.4528 9.4099
RPMI-6666 CTRP2 6.1184 8.1953 4.2485 1.7532
JVM-2 CTRP2 6.193 10.5641 3.1733 5.9014
Ci-1 CTRP2 6.2429 7.1888 4.7329 0.1719
HL-60 CTRP2 6.297 8.2594 4.3217 1.3087
AMO1 CTRP2 6.3347 10.0235 3.5307 4.26
SU-DHL-4 CTRP2 6.377 12.5558 2.3331 9.0117
Ki-JK CTRP2 6.4577 8.6357 4.2448 1.4222
KO52 CTRP2 6.4705 7.7889 4.6013 0.3549
K-562 CTRP2 6.4831 10.3841 3.4573 4.3505
Ri-1 CTRP2 6.491 9.2194 4.0037 2.2461
KE-97 CTRP2 6.5025 9.3962 3.9301 2.5054
MOLP-2 CTRP2 6.524 8.2876 4.4269 0.7858
NB4 CTRP2 6.5369 7.8386 4.6104 0.3056
JeKo-1 CTRP2 6.5397 8.5386 4.3299 1.071
RL CTRP2 6.5422 9.0277 4.1191 1.7777
SU-DHL-10 CTRP2 6.5615 7.7164 4.6656 0.19
OCI-M1 CTRP2 6.6153 7.8104 4.6524 0.1964
HEL 92.1.7 CTRP2 6.6384 7.879 4.6365 0.2171
SEM CTRP2 6.6886 50.7575 -16.4569 38.9121
Jurkat CTRP2 6.7028 8.5167 4.4185 0.6924
KMS-26 CTRP2 6.7034 7.8269 4.6801 0.1303
P31/FUJ CTRP2 6.7037 7.9115 4.6501 0.1748
NCI-H929 CTRP2 6.7187 8.5242 4.4229 0.6708
SU-DHL-6 CTRP2 6.7393 8.5757 4.4118 0.6885
KMM-1 CTRP2 6.752 10.2603 3.6848 3.1384
TF-1 CTRP2 6.7648 8.2075 4.5658 0.3073
SU-DHL-1 CTRP2 6.7922 7.6968 4.7561 0.039
KM-H2 CTRP2 6.7997 14.2423 1.8135 10.3848
SU-DHL-8 CTRP2 6.8529 8.301 4.5667 0.2736
NOMO-1 CTRP2 6.8548 8.1326 4.6285 0.1685
PF-382 CTRP2 6.8704 9.6213 4.0388 1.7443
EM-2 CTRP2 6.871 8.727 4.4117 0.6128
P12-Ichikawa CTRP2 6.8988 8.2256 4.612 0.1824
SKM-1 CTRP2 6.9203 7.8625 4.7445 0.0357
HEL CTRP2 6.9265 8.0038 4.6993 0.0695
KE-37 CTRP2 6.9313 8.8208 4.4017 0.6052
HT CTRP2 6.9348 8.1073 4.6669 0.1014
Karpas-299 CTRP2 6.9414 8.2581 4.6165 0.165
WSU-DLCL2 CTRP2 6.9545 7.9805 4.7168 0.0516
ME1 CTRP2 6.98 8.412 4.5761 0.2173
DND-41 CTRP2 6.995 11.2842 3.3614 4.0747
OCI-Ly3 CTRP2 7.0431 8.492 4.5716 0.2071
OCI-AML-2 CTRP2 7.0859 8.3174 4.6486 0.0966
HDLM-2 CTRP2 7.0862 15.2464 1.5286 11.0225
ST486 CTRP2 7.1064 9.6115 4.1643 1.1527
CML-T1 CTRP2 7.1201 8.5306 4.5869 0.1654
RPMI-8402 CTRP2 7.1531 8.6883 4.5432 0.2223
MV4-11 CTRP2 7.1602 8.7199 4.5346 0.2341
Karpas-422 CTRP2 7.161 8.9434 4.4528 0.3838
Mono-Mac-6 CTRP2 7.1782 11.0292 3.5877 3.0266
SUP-B15 CTRP2 7.1828 8.7271 4.5406 0.2183
Granta-519 CTRP2 7.1878 8.9342 4.4671 0.3455
MOLP-8 CTRP2 7.1911 8.661 4.5673 0.1765
P3HR-1 CTRP2 7.1939 9.0587 4.4231 0.4322
SUP-HD1 CTRP2 7.2145 9.4608 4.2763 0.7701
Raji CTRP2 7.2221 8.5836 4.6057 0.1211
OCI-Ly19 CTRP2 7.2277 9.5033 4.2655 0.791
CMK CTRP2 7.2283 8.3491 4.6873 0.0467
MM1.S CTRP2 7.2289 8.6927 4.5702 0.1641
M-07e CTRP2 7.2354 9.2086 4.3836 0.5001
Hs 611.T CTRP2 7.2446 8.9566 4.4815 0.2995
KMS-27 CTRP2 7.2769 8.4372 4.6745 0.0509
PL21 CTRP2 7.3141 8.6859 4.6035 0.1083
RPMI-8226 CTRP2 7.4067 8.874 4.5719 0.1276
EJM CTRP2 7.4076 9.2595 4.435 0.3302
Peer CTRP2 7.4134 8.7998 4.5997 0.0973
BV-173 CTRP2 7.4208 14.8792 1.9388 8.9825
MOLT-13 CTRP2 7.4757 9.0318 4.5422 0.1499
HuT 78 CTRP2 7.4913 9.6043 4.3408 0.4844
NALM-6 CTRP2 7.4971 9.4891 4.3862 0.3909
NCO2 CTRP2 7.501 9.1936 4.4947 0.2072
MHH-CALL-4 CTRP2 7.5177 9.238 4.4852 0.217
KHM-1B CTRP2 7.5365 8.9586 4.5889 0.0907
JURL-MK1 CTRP2 7.5623 9.0276 4.5746 0.1007
MOLM-13 CTRP2 7.6201 9.2709 4.5115 0.1598
JVM-3 CTRP2 7.7305 9.1454 4.5931 0.0657
MOLM-16 CTRP2 7.739 9.1455 4.5959 0.0629
SUP-T1 CTRP2 7.7415 9.3048 4.5432 0.1058
Reh CTRP2 7.7434 8.9778 4.6527 0.0305
MOLM-6 CTRP2 7.752 9.4864 4.4846 0.1676
GDM-1 CTRP2 7.7618 9.6937 4.4152 0.2605
MHH-CALL-3 CTRP2 7.8246 10.0495 4.3105 0.4198
Kasumi-1 CTRP2 7.908 9.427 4.5597 0.0726
L-1236 CTRP2 8.0474 10.1701 4.3534 0.6038
EHEB CTRP2 8.1302 9.8032 4.51 0.0874
LAMA-84 CTRP2 8.9536 23.8098 -1.3138 17.3938
KCL-22 CTRP2 9.4935 21.2379 0.2875 11.9393
⏷ Show the Full List of 138 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 4.9216 6.6989 4.1127 4.1601
TE15 CTRP2 5.184 8.5723 3.3954 6.666
KYSE-410 CTRP2 3.9777 5.6518 3.6722 8.2255
TE-14 CTRP2 5.0352 17.1207 -1.0015 23.1093
TE-6 CTRP2 5.0592 7.1901 3.9838 4.4295
KYSE-510 CTRP2 5.1265 7.0699 4.0992 3.8174
KYSE-30 CTRP2 5.1361 6.8962 4.1938 3.4024
TE-5 CTRP2 5.155 6.5606 4.3764 2.6017
TE-4 CTRP2 5.4319 7.5112 4.1171 3.2104
KYSE-150 CTRP2 5.4461 7.1703 4.2948 2.4548
EC-GI-10 CTRP2 7.1334 9.8905 4.0612 1.4488
TE-10 CTRP2 7.1452 9.394 4.2713 0.8237
COLO 680N CTRP2 7.2447 8.9962 4.467 0.3258
TE-9 CTRP2 7.293 8.7557 4.5717 0.1488
KYSE-450 CTRP2 7.3496 8.6603 4.6247 0.0825
OE21 CTRP2 7.4773 9.3207 4.4401 0.2994
TE-11 CTRP2 7.4982 10.4036 4.0284 1.2795
TE-1 CTRP2 7.5165 9.2529 4.4795 0.2257
KYSE-70 CTRP2 7.5533 8.8754 4.6227 0.0615
KYSE-180 CTRP2 7.6294 9.4526 4.4511 0.2399
OE33 CTRP2 7.742 9.5173 4.4701 0.1877
KYSE-140 CTRP2 7.787 9.7727 4.3965 0.2828
KYSE-520 CTRP2 8.127 9.942 4.462 0.1302
OE19 CTRP2 10.9422 22.8778 0.4317 9.7655
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 7.7733 9.3253 4.5474 0.0978
SW1990 CTRP2 4.5742 7.6921 3.3108 8.2482
SU.86.86 CTRP2 4.9263 5.9687 4.4805 2.6084
KP-4 CTRP2 4.9686 5.8283 4.5876 2.0714
Capan-1 CTRP2 5.347 10.9336 2.348 10.7221
PSN1 CTRP2 5.4014 11.2203 2.2487 11.0271
MIA PaCa-2 CTRP2 5.425 6.8984 4.4122 2.0063
Capan-2 CTRP2 5.4627 7.7221 4.0361 3.4961
Panc 08.13 CTRP2 5.6153 10.1259 2.9623 7.703
PaTu 8988s CTRP2 5.6364 8.4501 3.8062 4.1675
SNU-410 CTRP2 5.6503 9.2897 3.4031 5.8132
CFPAC-1 CTRP2 5.8985 8.1268 3.3029 1.1186
AsPC-1 CTRP2 5.9062 16.7324 -0.0978 18.7231
HuP-T4 CTRP2 5.9818 8.8599 3.85 3.4735
PANC-1 CTRP2 6.3513 8.1345 4.4046 0.985
Panc 04.03 CTRP2 6.5641 13.4578 2.0272 9.9257
QGP-1 CTRP2 6.6333 8.5802 4.3594 0.9087
PaTu 8902 CTRP2 6.6461 8.1788 4.5266 0.4457
Panc 02.03 CTRP2 6.7435 8.756 4.3406 0.8869
TCC-Pan2 CTRP2 6.861 8.2179 4.6003 0.2116
Panc 03.27 CTRP2 6.9108 13.4263 2.2885 8.3722
Panc 10.05 CTRP2 6.9759 8.5982 4.5061 0.3471
SUIT-2 CTRP2 7.0621 8.1837 4.6857 0.0647
SNU-213 CTRP2 7.0827 8.3497 4.6363 0.1104
L3.3 CTRP2 7.2247 8.545 4.62 0.1049
YAPC CTRP2 7.2479 8.5804 4.6161 0.1054
HPAC CTRP2 7.2505 8.6119 4.6062 0.1157
Panc 05.04 CTRP2 7.3847 8.8345 4.5776 0.1249
PaTu 8988t CTRP2 7.5639 31.1939 -5.9946 28.9407
DAN-G CTRP2 7.6117 42.1129 -11.3962 34.7532
Hs 766T CTRP2 7.6237 9.0357 4.5932 0.0767
PK-59 CTRP2 7.6923 9.2601 4.5412 0.1148
PK-45H CTRP2 7.6987 9.436 4.4827 0.1804
HuP-T3 CTRP2 7.7261 9.5442 4.4548 0.2115
BxPC-3 CTRP2 7.82 15.324 1.9929 8.2301
KP-2 CTRP2 8.5658 19.4195 0.5375 12.3649
KP-3 CTRP2 8.9187 21.6135 -0.2759 14.4609
HPAF-II CTRP2 11.4796 23.2277 0.5907 8.7094
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 5.0632 8.4359 3.3643 7.0254
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHP-212 CTRP2 4.5851 5.456 4.392 3.7806
SK-N-AS CTRP2 4.9875 6.0036 4.5166 2.3309
SK-N-DZ CTRP2 5.6158 7.7392 4.1384 2.8365
IMR-32 CTRP2 6.0797 7.1461 4.68 0.3621
SK-N-BE(2) CTRP2 6.8973 9.268 4.2038 1.1869
NH-6 CTRP2 7.1453 9.1761 4.3573 0.6036
CHP-126 CTRP2 7.1505 8.6947 4.5399 0.2283
SK-N-FI CTRP2 7.1679 8.7294 4.5341 0.2328
Kelly CTRP2 7.199 8.3354 4.6819 0.053
NB1 CTRP2 7.2622 8.6501 4.5972 0.1238
KP-N-SI9s CTRP2 7.4508 8.7521 4.6288 0.0673
SK-N-SH CTRP2 8.9353 25.4459 -2.1235 19.5068
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-869 CTRP2 5.5617 7.2411 4.3415 2.0927
HuH-28 CTRP2 6.6123 8.2082 4.5002 0.5288
HuCC-T1 CTRP2 7.2858 8.6969 4.5895 0.1286
SNU-1079 CTRP2 7.3509 19.7849 -0.5031 17.4992
SNU-478 CTRP2 7.4409 8.8137 4.6046 0.0889
SNU-1196 CTRP2 7.4767 8.764 4.6337 0.0609
SNU-308 CTRP2 7.488 8.679 4.6657 0.0396
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-673 CTRP2 4.6957 11.3373 1.6029 14.9963
SJSA-1 CTRP2 5.13 6.5598 4.3568 2.7294
CAL-78 CTRP2 6.3372 11.1577 2.9867 6.4413
Hs 888.T CTRP2 6.3381 10.8176 3.1519 5.773
TC71 CTRP2 6.448 11.5886 2.8554 6.8054
MG-63 CTRP2 6.4976 9.718 3.7791 3.081
SK-N-MC CTRP2 6.7948 7.8937 4.6902 0.0991
SW1353 CTRP2 6.9241 9.0954 4.2883 0.9157
SK-ES-1 CTRP2 6.9553 8.8578 4.3978 0.6022
HOS CTRP2 7.1578 14.0757 2.1455 8.5684
G-292 clone A141B1 CTRP2 7.3673 9.6696 4.2625 0.7219
SaOS-2 CTRP2 7.5021 14.9454 1.962 8.7803
MHH-ES-1 CTRP2 7.6211 9.4737 4.4404 0.2584
U2OS CTRP2 9.392 26.5612 -2.3413 19.3933
Hs 822.T CTRP2 10.7577 35.712 -5.8279 24.4705
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 71 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 CTRP2 -2.3411 -0.2739 -2.3418 49.2035
BT-20 CTRP2 4.6095 7.7689 3.3047 8.1973
CAL-85-1 CTRP2 4.7449 7.6032 3.5076 7.0618
T-47D CTRP2 5.3925 9.0032 3.347 6.4895
Hs 578Bst CTRP2 5.5995 11.1571 2.4374 9.8968
HCC1419 CTRP2 5.6236 7.2149 4.3956 1.791
HDQ-P1 CTRP2 5.9701 10.2886 3.148 6.3484
KPL-1 CTRP2 6.0626 7.1067 4.6879 0.3513
HCC2218 CTRP2 6.3311 11.6769 2.7298 7.489
CAL-120 CTRP2 6.4891 7.828 4.5942 0.3625
HMC-1-8 CTRP2 6.4971 7.6533 4.6633 0.215
MDA-MB-468 CTRP2 6.7143 9.3705 4.0634 1.8052
ZR-75-1 CTRP2 6.7391 7.8787 4.6751 0.1292
MDA-MB-361 CTRP2 6.8667 8.4615 4.5124 0.3776
MDA-MB-453 CTRP2 6.8757 10.5617 3.6213 3.2343
EFM-192A CTRP2 7.0198 10.1242 3.9005 2.0782
MDA-MB-157 CTRP2 7.0347 27.1347 -4.3891 27.1429
SK-BR-3 CTRP2 7.0498 9.4317 4.211 1.0547
CAL-51 CTRP2 7.0521 8.9517 4.4037 0.5388
BT-549 CTRP2 7.0537 8.9998 4.3858 0.5809
BT-474 CTRP2 7.0789 8.3999 4.6175 0.1336
MDA-MB-231 CTRP2 7.1692 8.9843 4.4408 0.405
CAMA-1 CTRP2 7.1915 8.6472 4.5723 0.1694
HCC1428 CTRP2 7.2154 9.1622 4.3928 0.4884
HCC202 CTRP2 7.2271 9.2328 4.3708 0.5325
HCC1395 CTRP2 7.4 14.5956 2.0606 8.5494
JIMT-1 CTRP2 7.4423 8.6196 4.6699 0.0404
HCC1806 CTRP2 7.464 8.8887 4.5872 0.1023
MCF-7 CTRP2 7.5968 9.5374 4.408 0.3183
HCC38 CTRP2 7.6172 9.3478 4.4836 0.1964
HCC1569 CTRP2 7.8176 9.7761 4.4069 0.2588
HCC1143 CTRP2 7.9361 10.0829 4.3422 0.3289
CAL-148 CTRP2 7.9556 25.2179 -2.7308 22.3837
HCC1937 CTRP2 8.0384 18.3663 0.6834 12.6223
MDA-MB-415 CTRP2 9.3853 20.5971 0.5198 11.3325
HCC1500 CTRP2 11.8073 29.3372 -2.0341 15.5908
AU565 CTRP2 11.8274 30.7527 -2.6913 17.1208
HCC1954 CTRP2 12.3347 27.8546 -1.0095 12.3789
BT 286 CTRP2 5.7754 7.6101 4.3076 1.9376
BT 333 CTRP2 5.8017 7.4759 4.3868 1.5988
BT 271 CTRP2 5.9508 11.2459 2.6628 8.3701
BT 139 CTRP2 5.9726 12.9413 1.8403 11.6412
BT 359 CTRP2 6.0431 8.6437 3.9934 2.8209
BT 444 CTRP2 6.0774 7.6151 4.4836 0.9596
BT 232 CTRP2 6.1133 8.2286 4.2303 1.8265
BT 504 CTRP2 6.1586 7.5598 4.5491 0.6824
BT 330 CTRP2 6.17 7.549 4.5592 0.6435
BT 328 CTRP2 6.1918 8.9579 3.9413 2.8335
BT 320 CTRP2 6.1936 7.3686 4.6434 0.393
BT 422 CTRP2 6.2343 7.4666 4.623 0.4229
BT 245 CTRP2 6.2395 9.4948 3.719 3.6422
BT 131 CTRP2 6.3728 8.0195 4.4638 0.7834
BT 498 CTRP2 6.4937 8.3386 4.3908 0.9163
BT 428 CTRP2 6.4951 8.3032 4.4063 0.868
BT 172 CTRP2 6.5107 8.3155 4.4089 0.8487
BT 239 CTRP2 6.5178 7.9106 4.5747 0.3942
BT 340 CTRP2 6.5243 8.6582 4.2708 1.2754
BT 145 CTRP2 6.6006 8.3315 4.4455 0.6817
BT 416 CTRP2 6.6544 10.8105 3.3673 4.4781
BT 216 CTRP2 6.716 8.6822 4.3576 0.8561
BT147 CTRP2 6.8034 8.518 4.4636 0.5189
BT 224 CTRP2 6.8089 8.5011 4.4726 0.4944
BT 440 CTRP2 6.8368 8.2394 4.5829 0.2491
BT 482 CTRP2 6.8658 8.0783 4.6518 0.1331
BT 112 CTRP2 6.8669 8.0311 4.6687 0.1114
BT 159 CTRP2 6.9387 11.7291 3.1181 5.0813
BT164 CTRP2 7.0265 8.1961 4.6691 0.0846
BT 179 CTRP2 7.0604 8.6727 4.5126 0.3037
BT 231 CTRP2 7.1282 9.1915 4.3438 0.6456
BT 187 CTRP2 7.6878 9.4774 4.4641 0.2074
BT 228 CTRP2 8.9689 15.7885 2.4831 5.0969
⏷ Show the Full List of 71 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 6.3418 7.5304 4.6454 0.3135
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KG-1-C CTRP2 2.8751 9.856 0.6563 22.7394
SF539 CTRP2 3.2329 5.921 2.7742 13.7386
SF268 CTRP2 4.0574 7.5756 2.8849 11.179
Hs 683 CTRP2 4.2325 6.3089 3.6527 7.6321
U-251MG CTRP2 4.4895 5.3191 4.3466 4.2175
T98G CTRP2 4.4993 7.6386 3.269 8.5855
CAS-1 CTRP2 4.5707 6.5767 3.8548 5.9966
KNS-60 CTRP2 4.9513 6.4705 4.2523 3.5136
SNU-738 CTRP2 5.0054 6.2411 4.4133 2.7291
KNS-42 CTRP2 5.1226 6.0437 4.6084 1.6873
GaMG CTRP2 5.2266 7.0433 4.1924 3.2447
SW1088 CTRP2 5.3414 7.406 4.1011 3.4277
DBTRG-05MG CTRP2 5.3525 14.0532 0.7941 16.7341
KNS-81 CTRP2 5.4837 7.0026 4.4028 1.9576
SNB-75 CTRP2 5.5091 8.977 3.4506 5.8537
YKG-1 CTRP2 5.6644 8.7762 3.6666 4.6988
KALS-1 CTRP2 5.7637 8.8461 3.7045 4.3859
SNU-489 CTRP2 6.1507 11.9345 2.4723 8.8162
D283 Med CTRP2 6.2851 9.6665 3.6675 3.7848
SF295 CTRP2 6.2985 10.6304 3.2148 5.5769
SNU-466 CTRP2 6.3904 7.6228 4.6307 0.3246
YH-13 CTRP2 6.4115 13.4394 1.9246 10.5722
Daoy CTRP2 6.5048 8.7072 4.2392 1.3983
LN-18 CTRP2 6.5914 7.5126 4.7486 0.0689
Becker CTRP2 6.6353 11.4605 3.0458 5.7734
SF126 CTRP2 6.6649 8.4675 4.4207 0.71
SNU-626 CTRP2 6.694 11.8707 2.8889 6.3142
SNU-1105 CTRP2 6.7785 7.7088 4.7474 0.0466
U-118MG CTRP2 6.8102 11.6515 3.0712 5.4336
CCF-STTG1 CTRP2 6.8181 8.6391 4.4226 0.6141
M059K CTRP2 6.8494 8.2829 4.572 0.265
U-87MG ATCC CTRP2 6.8708 8.2118 4.6063 0.199
42-MG-BA CTRP2 6.8899 8.729 4.4193 0.5833
GB-1 CTRP2 7.0723 9.4601 4.2101 1.0418
DK-MG CTRP2 7.1841 8.4986 4.6214 0.11
LN-229 CTRP2 7.2917 9.7436 4.1988 0.9313
8-MG-BA CTRP2 7.5581 39.1132 -9.9431 33.5651
A-172 CTRP2 7.5727 9.018 4.5815 0.0928
ONS-76 CTRP2 7.5793 9.157 4.5363 0.1381
GOS-3 CTRP2 7.6762 17.3673 0.9146 12.3562
GMS-10 CTRP2 7.7963 24.5252 -2.5085 22.1192
TM-31 CTRP2 7.9642 23.9682 -2.1081 20.9055
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-151 CTRP2 4.5755 5.846 4.2077 4.5404
JHUEM-1 CTRP2 4.7953 5.5359 4.5693 2.5361
MFE-296 CTRP2 4.8464 6.9636 3.9152 5.143
HEC-1-A CTRP2 5.1092 6.3399 4.4499 2.3767
EFE-184 CTRP2 5.5398 7.168 4.3618 2.0423
MFE-319 CTRP2 6.6863 11.1703 3.218 5.0222
HEC-6 CTRP2 6.8192 7.9636 4.6748 0.1131
RL95-2 CTRP2 6.8527 8.2843 4.5728 0.2624
JHUEM-7 CTRP2 6.8988 8.2857 4.5904 0.2171
HEC-251 CTRP2 6.9052 8.2928 4.5903 0.2154
ESS-1 CTRP2 6.9379 8.8199 4.405 0.5935
KLE CTRP2 7.0974 9.627 4.1535 1.1918
JHUEM-3 CTRP2 7.3364 9.6334 4.263 0.7372
HEC-59 CTRP2 7.3828 8.5151 4.6845 0.0365
HEC-108 CTRP2 7.406 8.7748 4.6056 0.0927
EN CTRP2 7.4064 8.8645 4.575 0.124
HEC-1-B CTRP2 7.6124 9.1388 4.5543 0.1134
AN3-CA CTRP2 7.7642 10.0528 4.2849 0.4918
JHUEM-2 CTRP2 8.2193 17.1026 1.4117 9.8209
HEC-50B CTRP2 13.0966 29.0895 -1.1149 11.8593
Ishikawa (Heraklio) 02 ER- CTRP2 7.1308 8.021 4.7624 0.0156
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR14TKB CTRP2 0.5153 3.5088 -3.9405 1.4657
UO-31 CTRP2 2.6022 6.3638 1.9307 18.7177
TUHR4TKB CTRP2 4.1601 7.8498 2.8505 11.0812
CAL-54 CTRP2 4.6804 7.0525 3.7229 6.2996
BFTC-909 CTRP2 5.3919 7.5992 4.0438 3.581
TUHR10TKB CTRP2 5.8651 8.3997 3.9916 3.0694
VMRC-RCZ CTRP2 5.9596 11.0395 2.7712 7.9119
KMRC-2 CTRP2 6.0777 8.6426 4.0163 2.6866
786-O CTRP2 6.3257 10.3265 3.3798 4.8745
RCC10RGB CTRP2 6.653 8.6298 4.3485 0.9271
KMRC-1 CTRP2 6.9137 10.062 3.869 2.2911
Caki-2 CTRP2 7.0078 9.8174 4.0273 1.6615
SNU-1272 CTRP2 7.0786 8.6179 4.5398 0.2491
A-498 CTRP2 7.1093 8.9833 4.4162 0.4835
Caki-1 CTRP2 7.1149 10.9841 3.5712 3.1542
OS-RC-2 CTRP2 7.1569 8.7057 4.5384 0.2288
KMRC-20 CTRP2 7.5222 8.9718 4.5794 0.1016
769-P CTRP2 7.5729 9.1421 4.5391 0.136
ACHN CTRP2 7.6913 9.3926 4.4951 0.1663
VMRC-RCW CTRP2 7.7259 9.0985 4.6071 0.0565
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-C5 CTRP2 4.4277 9.8993 2.0856 13.6296
SNU-C1 CTRP2 4.6118 7.3781 3.4999 7.3781
T84 CTRP2 4.6944 6.6962 3.9113 5.4842
KM12 CTRP2 4.8171 5.7069 4.5088 2.7319
SW1417 CTRP2 5.1507 12.6076 1.351 15.0594
MDST8 CTRP2 5.2722 7.526 3.988 4.0198
SW948 CTRP2 5.3402 7.0152 4.2934 2.6297
SNU-C4 CTRP2 5.4855 7.1509 4.3323 2.2416
CL-11 CTRP2 5.6133 7.6484 4.1807 2.6684
HCT 8 CTRP2 5.6593 8.5129 3.7921 4.189
COLO205 CTRP2 5.7152 13.2677 1.4775 13.5096
HCC-56 CTRP2 5.7504 6.9425 4.5991 0.8701
SNU-503 CTRP2 5.827 7.7564 4.2719 2.0108
COLO 320 CTRP2 6.1659 11.0232 2.9303 6.9313
DLD-1 CTRP2 6.5037 7.5569 4.7009 0.1486
LS1034 CTRP2 6.5373 9.7794 3.7752 3.0482
SNU-81 CTRP2 6.5449 12.3067 2.575 7.7845
HCT 116 CTRP2 6.5572 8.1685 4.4909 0.5845
OUMS-23 CTRP2 6.6288 7.623 4.724 0.0895
HCT 15 CTRP2 6.7036 14.1962 1.7668 10.7153
HT-29 CTRP2 6.748 7.7965 4.707 0.0883
HT-55 CTRP2 6.916 8.661 4.4571 0.479
NCI-H508 CTRP2 6.9418 8.4232 4.5572 0.2615
SK-CO-1 CTRP2 6.9839 8.6191 4.5016 0.3531
LS180 CTRP2 7.0018 8.3883 4.593 0.1849
LS411N CTRP2 7.0349 11.2424 3.4053 3.8613
RCM-1 [Human ESC] CTRP2 7.0388 8.784 4.4622 0.4131
LS123 CTRP2 7.0621 9.186 4.3162 0.7528
HT115 CTRP2 7.086 8.3278 4.6451 0.1003
SW620 CTRP2 7.2024 8.8163 4.5161 0.2526
SNU-61 CTRP2 7.233 8.9493 4.4796 0.3066
COLO201 CTRP2 7.243 8.6244 4.5991 0.125
SW48 CTRP2 7.2614 8.8216 4.5367 0.204
COLO 678 CTRP2 7.3398 9.9923 4.1207 1.1196
LS513 CTRP2 7.4099 8.8238 4.5903 0.1072
C2BBe1 CTRP2 7.4768 9.1805 4.4903 0.2195
LoVo CTRP2 7.5262 9.4511 4.4118 0.3336
GP2d CTRP2 7.6713 9.4246 4.4766 0.1941
RKO CTRP2 7.6874 18.4995 0.372 14.1932
CCK-81 CTRP2 7.7744 9.4564 4.503 0.1421
NCI-H716 CTRP2 8.0462 9.8272 4.4726 0.1315
SNU-407 CTRP2 8.1867 9.8299 4.5205 0.074
CW-2 CTRP2 8.2652 9.977 4.4982 0.0825
SNU-C2A CTRP2 10.0867 27.1146 -2.1237 17.9323
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-761 CTRP2 4.2692 5.6848 3.9662 6.2913
JHH-5 CTRP2 4.6484 5.536 4.4222 3.4956
SNU-878 CTRP2 4.6628 6.5736 3.9424 5.4252
SNU-387 CTRP2 4.9304 6.756 4.0918 4.2295
SNU-449 CTRP2 4.9981 8.4268 3.3144 7.361
SNU-886 CTRP2 5.1738 6.4689 4.4369 2.3145
HuH-6 CTRP2 5.2243 8.2408 3.5935 5.7601
JHH-1 CTRP2 5.6604 10.893 2.6163 9.0548
JHH-2 CTRP2 6.3408 9.8535 3.6154 3.9162
JHH-6 CTRP2 6.6646 7.5137 4.7736 0.0386
SNU-182 CTRP2 6.6916 12.258 2.7009 7.0651
SNU-475 CTRP2 6.7815 9.7355 3.9395 2.1737
PLC/PRF/5 CTRP2 6.8512 13.1922 2.3603 8.1786
JHH-4 CTRP2 7.0112 13.8116 2.172 8.679
Hep 3B2.1-7 CTRP2 7.0262 8.4558 4.5781 0.2014
SNU-423 CTRP2 7.0922 9.8284 4.0664 1.465
SNU-398 CTRP2 7.14 8.9209 4.4526 0.3923
HLF CTRP2 7.1443 10.1358 3.9623 1.758
Li-7 CTRP2 7.2972 19.6016 -0.4527 17.4332
Hep-G2 CTRP2 7.3713 8.8561 4.5653 0.1416
SK-HEP-1 CTRP2 7.4491 15.7547 1.5367 10.4485
HuH-1 CTRP2 9.4221 38.4156 -8.1481 29.351
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 136 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1666 CTRP2 3.0354 7.3858 1.9558 17.4462
NCI-H358 CTRP2 3.6178 6.6284 2.8858 12.2638
NCI-H1563 CTRP2 3.6418 7.0878 2.7045 12.9244
HOP-62 CTRP2 3.7028 5.7929 3.3246 10.3221
NCI-H1341 CTRP2 3.711 6.0725 3.2204 10.7023
NCI-H2087 CTRP2 3.8787 5.5027 3.6231 8.6907
NCI-H1573 CTRP2 3.9458 5.1707 3.8087 7.8038
NCI-H1355 CTRP2 4.0057 6.1249 3.5046 8.8033
NCI-H810 CTRP2 4.1572 5.1175 4.0553 6.2696
EKVX CTRP2 4.1707 5.8197 3.8066 7.1791
NCI-H1944 CTRP2 4.2192 6.0558 3.7537 7.2616
NCI-H1693 CTRP2 4.3074 6.5449 3.617 7.5925
NCI-H446 CTRP2 4.3355 6.7038 3.5691 7.7205
NCI-H1703 CTRP2 4.3704 7.2329 3.3478 8.5483
HCC4006 CTRP2 4.5536 5.1024 4.4919 3.488
NCI-H1155 CTRP2 4.5618 5.2086 4.4653 3.5628
NCI-H647 CTRP2 4.6123 7.3122 3.5329 7.2395
DV-90 CTRP2 4.6166 5.3807 4.4565 3.4441
DMS 53 CTRP2 4.676 11.8829 1.3135 16.1581
NCI-H1581 CTRP2 4.681 6.1343 4.1733 4.4288
HOP-92 CTRP2 4.767 9.1793 2.7414 10.2205
DMS 454 CTRP2 4.7691 7.6143 3.5233 6.9455
COLO 668 CTRP2 4.7975 6.0838 4.3069 3.612
NCI-H1105 CTRP2 4.7988 6.2376 4.2325 3.9184
LCLC-97TM1 CTRP2 4.8063 7.854 3.4365 7.2322
NCI-H2106 CTRP2 4.8411 6.6967 4.0433 4.6174
HCC1195 CTRP2 4.8481 7.0497 3.8738 5.3126
NCI-H2110 CTRP2 4.8891 7.1373 3.8659 5.2617
Lu-99 CTRP2 4.9964 5.7751 4.6383 1.8022
ChaGo-K-1 CTRP2 5.007 7.2071 3.9318 4.7493
Sq-1 CTRP2 5.021 8.2365 3.4288 6.836
SK-MES-1 CTRP2 5.0335 6.9601 4.0774 4.0857
NCI-H1915 CTRP2 5.1166 7.9159 3.6683 5.6462
NCI-H520 CTRP2 5.1605 6.5081 4.4069 2.4636
NCI-H2228 CTRP2 5.1801 7.3634 3.9959 4.1521
EPLC-272H CTRP2 5.1805 7.5459 3.9051 4.5324
NCI-H522 CTRP2 5.2199 6.7726 4.3219 2.7148
NCI-H1650 CTRP2 5.2207 7.3452 4.0374 3.9045
NCI-H2170 CTRP2 5.2378 7.6189 3.9145 4.3888
NCI-H2444 CTRP2 5.2412 6.8647 4.2926 2.7999
HARA [Human squamous cell lung carcinoma] CTRP2 5.2423 7.0003 4.2261 3.0762
HCC15 CTRP2 5.2447 6.7508 4.3519 2.5464
HCC1438 CTRP2 5.4829 7.3002 4.2577 2.5502
SW1271 CTRP2 5.4857 7.6271 4.0998 3.1954
COR-L51 CTRP2 5.5522 9.2827 3.3322 6.2734
KNS-62 CTRP2 5.558 6.891 4.506 1.4424
HCC44 CTRP2 5.6356 15.6473 0.2272 18.1627
NCI-H1734 CTRP2 5.7101 10.1908 3.0028 7.3733
PC-14 CTRP2 5.797 7.826 4.2197 2.2546
LUDLU-1 CTRP2 5.8248 7.7028 4.2957 1.921
NCI-H889 CTRP2 5.8711 7.5097 4.4136 1.417
DMS 114 CTRP2 5.9082 7.827 4.2902 1.8395
LK2 CTRP2 5.9241 8.6951 3.8899 3.3943
NCI-H211 CTRP2 5.9638 12.8621 1.8728 11.5282
Calu-1 CTRP2 5.9751 8.0986 4.2056 2.0821
NCI-H322 CTRP2 6.0794 9.9931 3.3705 5.2703
NCI-H2081 CTRP2 6.1007 9.1906 3.7717 3.6212
NCI-H524 CTRP2 6.2056 14.3942 1.2984 13.32
NCI-H1793 CTRP2 6.2634 11.9107 2.5665 8.2544
HCC2935 CTRP2 6.285 10.6643 3.1891 5.7005
BEN CTRP2 6.4154 7.5114 4.6829 0.2062
NCI-H2196 CTRP2 6.4852 9.8604 3.7051 3.3803
NCI-H526 CTRP2 6.495 8.587 4.286 1.2507
NCI-H1568 CTRP2 6.4971 9.1702 4.0295 2.1452
NCI-H841 CTRP2 6.5001 12.6374 2.3821 8.6233
LOU-NH91 CTRP2 6.5513 9.5362 3.8954 2.5797
NCI-H1838 CTRP2 6.5689 11.8674 2.8047 6.8301
SBC-5 CTRP2 6.598 7.5003 4.7551 0.0615
NCI-H226 CTRP2 6.649 7.935 4.6202 0.2436
NCI-H196 CTRP2 6.669 14.2105 1.7347 10.8934
MOR/CPR CTRP2 6.6995 7.6277 4.7474 0.0554
LCLC-103H CTRP2 6.7508 8.0208 4.6289 0.196
NCI-H2029 CTRP2 6.7679 8.5331 4.4419 0.5923
NCI-H1435 CTRP2 6.7739 8.7711 4.349 0.8418
A-549 CTRP2 6.7743 9.4407 4.0655 1.7417
NCI-H460 CTRP2 6.7872 8.1523 4.5953 0.2431
HCC2108 CTRP2 6.8796 8.8442 4.369 0.7197
DMS 273 CTRP2 6.8821 9.9469 3.9022 2.2051
LC-1/sq-SF CTRP2 6.9074 8.2679 4.6001 0.1987
COR-L95 CTRP2 6.9197 8.2226 4.621 0.1637
IA-LM CTRP2 6.9263 8.4874 4.5273 0.3235
Calu-3 CTRP2 6.9446 9.1041 4.2946 0.8845
NCI-H2286 CTRP2 6.945 8.8674 4.3895 0.6289
COR-L105 CTRP2 6.948 10.579 3.6565 3.023
HCC827 CTRP2 6.9693 12.7723 2.643 6.8985
NCI-H2126 CTRP2 7.0301 8.184 4.6744 0.0789
DMS 79 CTRP2 7.0509 8.9698 4.3962 0.5573
NCI-H1755 CTRP2 7.1434 12.7788 2.7554 6.2227
HCC95 CTRP2 7.1633 8.5412 4.5991 0.14
HCC366 CTRP2 7.1696 8.8145 4.5039 0.2835
NCI-H650 CTRP2 7.2111 9.3456 4.3202 0.6607
Calu-6 CTRP2 7.2411 8.934 4.4884 0.2883
HCC1833 CTRP2 7.2473 14.6979 1.9073 9.3513
NCI-H441 CTRP2 7.2672 8.9409 4.4961 0.2671
NCI-H1869 CTRP2 7.2736 13.4052 2.5439 6.8676
HCC78 CTRP2 7.2827 8.6652 4.5994 0.1178
SHP-77 CTRP2 7.2878 8.4349 4.679 0.047
NCI-H1092 CTRP2 7.3343 9.3449 4.3734 0.4798
NCI-H2030 CTRP2 7.3688 9.1182 4.4713 0.2788
NCI-H838 CTRP2 7.3697 8.8116 4.5801 0.1246
VMRC-LCD CTRP2 7.3836 8.8728 4.5639 0.1409
NCI-H292 CTRP2 7.4373 8.6718 4.651 0.0525
NCI-H2122 CTRP2 7.4375 8.6141 4.6701 0.0407
NCI-H2172 CTRP2 7.4443 8.7663 4.6218 0.0736
NCI-H2023 CTRP2 7.4763 9.0626 4.5316 0.1629
NCI-H1395 CTRP2 7.4884 9.7555 4.282 0.6151
NCI-H23 CTRP2 7.5238 9.3809 4.4363 0.2919
NCI-H1299 CTRP2 7.5515 9.0557 4.5611 0.1156
HCC1588 CTRP2 7.5659 8.9544 4.6006 0.0772
NCI-H1184 CTRP2 7.5745 9.56 4.391 0.3555
RERF-LC-MS CTRP2 7.5767 9.1587 4.5347 0.1403
NCI-H2405 CTRP2 7.5803 9.9704 4.2388 0.672
NCI-H2342 CTRP2 7.5976 9.8003 4.311 0.5036
HCC2279 CTRP2 7.5993 9.3724 4.4682 0.222
RERF-LC-Ad2 CTRP2 7.625 9.0502 4.5887 0.0801
T3M-10 CTRP2 7.6327 9.3506 4.4883 0.1867
SK-LU-1 CTRP2 7.6343 9.0935 4.5774 0.0887
NCI-H1339 CTRP2 7.6446 13.7155 2.6368 6.033
NCI-H2291 CTRP2 7.7094 9.2746 4.5422 0.1113
NCI-H1792 CTRP2 7.7103 9.5168 4.4586 0.2099
NCI-H2009 CTRP2 7.7794 9.3357 4.546 0.0983
NCI-H1651 CTRP2 7.7802 9.6973 4.4209 0.2474
EBC-1 CTRP2 7.8034 9.3959 4.534 0.1061
NCI-H1623 CTRP2 7.8185 9.4725 4.5132 0.1243
RERF-LC-A1 CTRP2 7.8221 9.25 4.5894 0.0599
COLO 699 CTRP2 7.8643 9.4271 4.5447 0.0891
NCI-H2085 CTRP2 7.8857 9.7441 4.4436 0.1925
NCI-H727 CTRP2 7.9183 9.5601 4.5185 0.1053
NCI-H661 CTRP2 7.9765 9.7017 4.4908 0.1235
LXF 289 CTRP2 7.9809 9.8722 4.4337 0.1861
NCI-H1373 CTRP2 8.1287 9.73 4.534 0.07
NCI-H1694 CTRP2 8.2256 18.9501 0.5309 12.8663
HCC1171 CTRP2 9.9216 21.0547 0.6468 10.2592
RERF-LC-Ad1 CTRP2 11.5682 28.5928 -1.8379 15.3846
SW1573 CTRP2 11.5937 28.2248 -1.6479 14.8755
Hs 888.Lu CTRP2 7.6673 10.5577 4.0459 1.1187
⏷ Show the Full List of 136 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 6.0811 8.1214 4.26 1.7522
Yamato-SS CTRP2 6.3749 10.387 3.3841 4.7886
MES-SA CTRP2 2.5674 9.0957 0.7094 23.3544
Rh18 CTRP2 3.4916 6.2309 2.9249 12.4452
GCT CTRP2 3.6617 8.2389 2.1869 14.9561
HT-1080 CTRP2 4.6248 6.7659 3.8131 6.0469
TE 441.T CTRP2 4.7288 5.9239 4.3203 3.7131
KYM-1 CTRP2 5.0512 7.3541 3.8952 4.8173
Hs 729.T CTRP2 5.4801 7.9499 3.9369 3.879
TE 617.T CTRP2 5.663 7.2147 4.4213 1.6382
BT-12 CTRP2 5.7515 7.1674 4.4983 1.2364
SK-LMS-1 CTRP2 6.2189 10.451 3.2463 5.5665
BT-16 CTRP2 6.7476 8.0086 4.632 0.1917
Rh41 CTRP2 6.9539 8.7335 4.4456 0.4879
SW982 CTRP2 6.9955 8.8267 4.4275 0.5101
G-402 CTRP2 7.0327 11.1605 3.4417 3.7268
Tm87-16 CTRP2 7.0817 8.4307 4.6078 0.1455
TTC-709 CTRP2 7.097 9.5486 4.1857 1.0961
A-204 CTRP2 7.2314 10.7787 3.7294 2.4689
SK-UT-1 CTRP2 7.3805 8.9296 4.543 0.1679
RKN CTRP2 7.3953 8.382 4.7319 0.0159
G-401 CTRP2 7.4976 10.2517 4.09 1.1033
RD CTRP2 8.4305 10.2966 4.4479 0.104
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 6.4773 7.6079 4.6721 0.2054
P-STS CTRP2 6.8841 8.4154 4.5369 0.3201
SYO-1 CTRP2 7.2112 10.353 3.9042 1.892
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 7.3158 9.2205 4.4125 0.4058
OV7 CTRP2 4.2677 8.4207 2.6721 11.5724
A2780 CTRP2 4.2818 5.6653 3.9875 6.1745
TYK-nu CTRP2 4.3828 5.7095 4.0736 5.5682
OVCAR-5 CTRP2 4.5089 7.3585 3.4156 7.9553
OAW42 CTRP2 4.6596 5.1622 4.5873 2.8234
OC 314 CTRP2 4.6815 6.2382 4.1234 4.6338
TOV-112D CTRP2 5.2508 7.306 4.0807 3.6697
COV362 CTRP2 5.4439 9.5309 3.1248 7.327
EFO-27 CTRP2 6.0532 15.0611 0.8499 15.2342
OVTOKO CTRP2 6.1035 11.4367 1.9266 6.2242
OV56 CTRP2 6.5242 7.9161 4.5754 0.3895
SNU-840 CTRP2 6.7088 9.9808 3.7867 2.807
TOV-21G CTRP2 6.7968 8.5749 4.4384 0.5854
JHOM-1 CTRP2 6.8116 8.3562 4.5292 0.3646
EFO-21 CTRP2 6.842 13.3777 2.2641 8.5696
SNU-8 CTRP2 6.8655 7.9269 4.704 0.0733
OVISE CTRP2 6.8938 7.8797 4.7298 0.0481
OVK18 CTRP2 7.0706 8.6106 4.5394 0.2523
COV644 CTRP2 7.0906 8.6511 4.5325 0.2581
JHOS-2 CTRP2 7.108 8.8635 4.461 0.3878
DOV13 CTRP2 7.1083 8.4944 4.5953 0.1565
OVSAHO CTRP2 7.1808 8.5662 4.5968 0.1395
ONCO-DG-1 CTRP2 7.2155 8.564 4.6101 0.1172
SK-OV-3 CTRP2 7.229 8.9051 4.4942 0.282
ES2 CTRP2 7.2324 13.2724 2.5798 6.7842
COV434 CTRP2 7.3108 9.4135 4.3373 0.5707
SNU-119 CTRP2 7.3235 9.1531 4.4407 0.348
OV-90 CTRP2 7.3627 9.4284 4.3536 0.5106
Caov-3 CTRP2 7.4766 8.767 4.6327 0.0617
HEY A8 CTRP2 7.5828 8.9632 4.6034 0.073
MCAS CTRP2 7.6 9.3715 4.4688 0.221
JHOC-5 CTRP2 7.6255 8.8256 4.6634 0.0321
Kuramochi CTRP2 7.827 9.5752 4.4809 0.1582
OVCAR-8 CTRP2 7.8317 9.1997 4.6093 0.0469
RMG-I CTRP2 8.1448 10.0916 4.417 0.1758
OAW28 CTRP2 8.168 10.1961 4.3891 0.2051
OVCAR-4 CTRP2 8.1756 9.9975 4.4602 0.1251
IGROV-1 CTRP2 8.271 10.1109 4.4551 0.1171
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2452 CTRP2 4.8485 8.541 3.1303 8.4305
MPP 89 CTRP2 5.4579 8.4866 3.6546 5.0908
ACC-MESO-1 CTRP2 6.8866 9.9332 3.9109 2.1702
MSTO-211H CTRP2 7.3083 19.9308 -0.6066 17.8782
IST-Mes1 CTRP2 7.3604 26.2663 -3.7036 25.3533
NCI-H28 CTRP2 7.4808 9.3691 4.4239 0.3266
NCI-H2052 CTRP2 7.5013 8.8914 4.5994 0.0859
JL-1 CTRP2 7.815 9.1357 4.6248 0.0397
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU145 CTRP2 5.7589 8.7815 3.7326 4.2781
LNCaP clone FGC CTRP2 7.3373 9.4432 4.3372 0.5586
PaCa-3 CTRP2 7.4951 14.2244 2.301 7.5025
VCaP CTRP2 7.7968 9.2473 4.5817 0.0675
22Rv1 CTRP2 7.9415 16.2348 1.6404 9.3696
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 CTRP2 1.4451 7.9868 0.0514 28.7352
YD-15 CTRP2 6.0388 9.9585 3.3587 5.3798
Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
WM115 CTRP2 -0.8877 2.3282 -0.9376 39.6684
WT2-iPS CTRP2 -0.3475 3.8308 -0.5586 36.5642
HT-144 CTRP2 0.2499 5.5004 -0.3193 33.7303
COLO 829 CTRP2 0.3354 6.8422 -0.6774 34.4332
Malme-3M CTRP2 0.4021 4.9793 -0.0043 32.2519
UACC-62 CTRP2 0.5364 6.6622 -0.3957 32.9715
SK-MEL-24 CTRP2 0.7343 7.8801 -0.6518 33.0275
WM983B CTRP2 0.8307 5.835 0.208 30.1561
UACC-257 CTRP2 1.3193 6.2618 0.5919 27.3362
WM266-4 CTRP2 1.3899 6.0891 0.7289 26.6478
A2058 CTRP2 1.9867 51.0038 -20.5306 45.0784
SK-MEL-1 CTRP2 2.2179 11.2898 -0.6617 28.6601
COLO 800 CTRP2 2.4082 13.7443 -1.6593 30.7265
Mel Ho CTRP2 2.4597 14.0474 -1.7584 30.8261
RVH-421 CTRP2 2.4628 10.2463 0.0699 25.7946
IGR-37 CTRP2 2.5991 8.4989 1.0141 22.1736
IGR-1 CTRP2 4.2045 9.126 2.2674 13.3753
RPMI-7951 CTRP2 4.2479 5.59 3.983 6.2839
Hs 294T CTRP2 4.4558 11.0544 1.5358 15.761
WM1799 CTRP2 4.4572 13.5574 0.2892 20.3156
A101D CTRP2 4.8654 21.5137 -3.3399 28.9206
Hs 895.T CTRP2 4.8695 8.9154 2.9612 9.096
MeWo CTRP2 5.1652 7.9782 3.6769 5.5193
Hs 688(A).T CTRP2 5.4665 8.7927 3.5093 5.6821
SK-MEL-3 CTRP2 5.4709 14.6485 0.593 17.2213
WM793 CTRP2 5.6601 13.3729 1.3815 13.9776
K029AX CTRP2 5.9908 12.5663 2.0401 10.819
MDA-MB-435S CTRP2 6.0437 14.0039 1.3678 13.3406
COLO 741 CTRP2 6.1088 24.5531 -3.8377 27.6433
SK-MEL-28 CTRP2 6.1609 19.137 -1.0944 21.2438
Hs 839.T CTRP2 6.2214 10.7641 3.0962 6.1718
A-375 CTRP2 6.3846 12.8589 2.19 9.5694
COLO 792 CTRP2 6.6327 18.5544 -0.4369 18.493
CJM [Human melanoma] CTRP2 6.6927 7.8439 4.6701 0.1471
SK-MEL-30 CTRP2 6.8943 8.2081 4.6165 0.1766
G-361 CTRP2 6.9369 12.9102 2.555 7.2897
Hs 936.T CTRP2 6.9835 8.0862 4.6913 0.0694
IPC-298 CTRP2 7.088 8.1891 4.6928 0.0561
Hs 852.T CTRP2 7.1283 8.6155 4.5598 0.2029
Hs 944.T CTRP2 7.1799 9.8132 4.1168 1.2422
Mel JuSo CTRP2 7.2205 8.5447 4.6186 0.1071
LOX-IMVI CTRP2 7.3624 8.8183 4.5752 0.1316
SK-MEL-31 CTRP2 8.0788 15.7521 1.9589 8.0165
SK-MEL-5 CTRP2 8.0942 14.9571 2.3404 6.5878
Hs 940.T CTRP2 8.9393 29.0412 -3.883 23.3764
IGR-39 CTRP2 10.2588 32.2599 -4.5004 22.7947
HMCB CTRP2 11.824 28.7308 -1.7378 14.8365
⏷ Show the Full List of 47 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-16 CTRP2 2.1262 3.6984 2.1024 19.5216
ECC10 CTRP2 3.7477 4.6986 3.7065 8.7793
SNU-216 CTRP2 4.577 7.3897 3.4625 7.6098
LMSU CTRP2 4.7491 7.8603 3.3834 7.5733
Hs 746.T CTRP2 4.812 5.7199 4.4977 2.7896
SNU-601 CTRP2 4.9848 5.9804 4.5258 2.2978
KATO III CTRP2 5.1269 10.1324 2.5688 10.2276
OCUM-1 CTRP2 5.4831 7.7333 4.0458 3.4229
MKN1 CTRP2 5.8858 8.4463 3.9833 3.0737
GSU CTRP2 5.9869 6.5771 4.8542 0.0528
KE-39 CTRP2 6.2983 9.8752 3.5771 4.1255
MKN45 CTRP2 6.5136 7.4581 4.7395 0.0924
SNU-5 CTRP2 6.791 8.2116 4.5749 0.2798
SNU-620 CTRP2 6.794 7.9049 4.6861 0.1042
SNU-1 CTRP2 6.8283 8.9712 4.2931 0.9675
ECC12 CTRP2 6.9293 7.9186 4.7289 0.0453
HGC-27 CTRP2 6.9425 8.7815 4.422 0.5493
23132/87 CTRP2 6.9484 8.4438 4.5522 0.2683
SH-10-TC CTRP2 7.0849 9.1421 4.3439 0.6685
SNU-668 CTRP2 7.1508 8.8063 4.4995 0.2975
AGS CTRP2 7.2091 8.4533 4.6457 0.0816
NUGC-3 CTRP2 7.24 8.6812 4.5783 0.1511
GSS CTRP2 7.2698 8.697 4.5837 0.1385
NUGC-4 CTRP2 7.406 9.0429 4.5125 0.2043
Fu97 CTRP2 7.433 9.0666 4.5142 0.1955
MKN7 CTRP2 7.4482 10.6891 3.8841 1.7586
SNU-719 CTRP2 7.4578 9.1375 4.4984 0.2122
MKN74 CTRP2 7.6733 9.5662 4.4271 0.2652
HuG1-N CTRP2 7.6804 9.6397 4.4034 0.3013
NCI-N87 CTRP2 7.8573 9.8605 4.3919 0.2715
IM95 CTRP2 7.8641 9.701 4.4507 0.1878
SNG-M CTRP2 5.1162 7.05 4.1008 3.8297
SNU-1077 CTRP2 6.693 8.194 3.6064 0.1061
SNU-685 CTRP2 7.2076 8.3642 4.6752 0.0571
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TT2609-C02 CTRP2 3.5183 6.5387 2.8225 12.7746
SW579 CTRP2 4.0487 6.5407 3.3625 9.2598
ML-1 [Human leukemia] CTRP2 4.279 6.4873 3.6162 7.6646
8505C CTRP2 4.6683 19.35 -2.4242 27.4044
8305C CTRP2 4.688 14.0731 0.2297 20.0301
B-CPAP CTRP2 6.0136 16.7602 -0.0267 18.2982
CGTH-W-1 CTRP2 6.6712 8.5557 4.3879 0.7988
CAL-62 CTRP2 6.7234 7.9425 4.6465 0.1751
FTC-133 CTRP2 6.7659 10.7171 3.4822 3.8915
TT CTRP2 7.3245 8.8095 4.5645 0.1516
BHT-101 CTRP2 7.8019 19.2054 0.1097 14.8778
FTC-238 CTRP2 13.099 46.3141 -9.3238 26.6932
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-33 CTRP2 4.3649 5.7145 4.053 5.6965
FaDu CTRP2 4.4842 5.1467 4.4023 4.0232
YD-8 CTRP2 4.4864 7.699 3.2276 8.7861
HSC-2 CTRP2 4.6256 7.0754 3.6618 6.6738
PE/CA-PJ49 CTRP2 4.8539 5.435 4.6742 1.9676
HSC-4 CTRP2 4.942 6.9295 4.0152 4.5278
PE/CA-PJ15 CTRP2 5.3547 7.8739 3.8792 4.3304
PE/CA-PJ34 (clone C12) CTRP2 5.4548 8.4539 3.6684 5.0384
PE/CA-PJ41 (clone D2) CTRP2 5.4618 6.7764 4.4967 1.6103
BICR 56 CTRP2 5.8469 8.5286 3.9172 3.3948
BICR 22 CTRP2 6.2408 9.9628 3.4967 4.5259
SNU-1214 CTRP2 6.4706 11.1141 3.1001 5.7894
SNU-1076 CTRP2 6.4912 7.5876 4.685 0.1781
SNU-46 CTRP2 6.5113 11.3051 3.0361 5.9872
BICR 18 CTRP2 6.9293 8.9898 4.3336 0.7856
YD-10B CTRP2 6.9622 8.5541 4.5169 0.3305
HSC-3 CTRP2 7.0541 8.3292 4.6331 0.1193
SCC-9 CTRP2 7.0756 9.742 4.0944 1.3897
SNU-899 CTRP2 7.2382 12.7751 2.8187 5.8533
SCC-25 CTRP2 7.2674 9.439 4.3085 0.6603
SNU-1066 CTRP2 7.4479 9.072 4.5179 0.187
SCC-4 CTRP2 7.4542 8.9094 4.5767 0.1145
BHY CTRP2 7.4786 8.834 4.6109 0.0787
BICR 31 CTRP2 7.6333 9.3978 4.4719 0.2088
SNU-1041 CTRP2 7.8415 9.4411 4.532 0.1029
BICR 16 CTRP2 8.7803 22.6165 -0.8565 16.3692
CAL-27 CTRP2 10.1395 38.1828 -7.494 27.6545
BICR 6 CTRP2 11.3183 25.2771 -0.4441 11.9417
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
253J CTRP2 3.9454 7.0257 3.0359 10.8338
U-BLC1 CTRP2 4.0319 12.3282 0.5278 20.4242
UM-UC-1 CTRP2 4.4312 6.234 3.8844 6.2047
HT-1197 CTRP2 4.8544 7.4941 3.6578 6.2056
BC-3C CTRP2 5.0358 8.6185 3.2502 7.5571
T24 CTRP2 5.2752 8.9121 3.2994 6.9003
SCaBER CTRP2 5.5799 7.6727 4.1453 2.8623
UM-UC-3 CTRP2 5.6929 8.6738 3.7377 4.3602
SW1710 CTRP2 5.7184 7.5253 4.3106 2.0001
KU-19-19 CTRP2 5.9026 7.1444 3.6845 0.1588
J82 CTRP2 5.9618 10.2759 3.1482 6.3608
CAL-29 CTRP2 6.0903 7.7082 4.45 1.0615
TCCSUP CTRP2 6.4821 8.591 4.2774 1.2903
253J-BV CTRP2 6.858 8.5409 4.4784 0.4569
639V CTRP2 6.9613 8.0692 4.6893 0.0742
RT-112 CTRP2 7.2311 8.4937 4.6397 0.0842
JMSU-1 CTRP2 7.4433 8.5841 4.682 0.0339
KMBC-2 CTRP2 7.5593 12.6545 3.0749 4.491
RT-4 CTRP2 7.6801 9.5815 4.4242 0.2679
HT-1376 CTRP2 7.7773 10.0429 4.2939 0.4687
VM-CUB-1 CTRP2 8.2624 10.1246 4.4475 0.1253
5637 CTRP2 8.617 17.8119 1.336 9.5636
647V CTRP2 10.526 36.2921 -6.2799 25.4599
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 6.0677 7.2611 4.6281 0.5119

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vemurafenib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Arry-162 DM1P6FR Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Arry-162. Melanoma [2C30] [15]
Selumetinib DMC7W6R Moderate Increased metabolism of Vemurafenib caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vemurafenib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [17]
Coadministration of a Drug Treating the Disease Different from Vemurafenib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Vemurafenib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [15]
Metreleptin DM1NOEK Moderate Increased metabolism of Vemurafenib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [18]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Vemurafenib and Ivosidenib. Acute myeloid leukaemia [2A60] [19]
Arn-509 DMT81LZ Major Increased metabolism of Vemurafenib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Vemurafenib and Gilteritinib. Acute myeloid leukaemia [2A60] [19]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Vemurafenib and Oliceridine. Acute pain [MG31] [19]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Vemurafenib and Ivabradine. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Vemurafenib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Vemurafenib and Levalbuterol. Asthma [CA23] [20]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Vemurafenib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [18]
Ag-221 DMS0ZBI Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [15]
Erdafitinib DMI782S Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [21]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Vemurafenib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [22]
Talazoparib DM1KS78 Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [23]
LY2835219 DM93VBZ Moderate Increased metabolism of Vemurafenib caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Vemurafenib caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Tucatinib DMBESUA Moderate Decreased metabolism of Vemurafenib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Palbociclib DMD7L94 Moderate Increased metabolism of Vemurafenib caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Alpelisib DMEXMYK Moderate Increased metabolism of Vemurafenib caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Macitentan DMP79A1 Moderate Increased metabolism of Vemurafenib caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [27]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Vemurafenib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [19]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Vemurafenib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [28]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Vemurafenib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [20]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Vemurafenib caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [25]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Vemurafenib and Osilodrostat. Cushing syndrome [5A70] [19]
Lumacaftor DMCLWDJ Major Increased metabolism of Vemurafenib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [15]
Vortioxetine DM6F1PU Moderate Increased metabolism of Vemurafenib caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [29]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Vemurafenib and Deutetrabenazine. Dystonic disorder [8A02] [19]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Vemurafenib and Ingrezza. Dystonic disorder [8A02] [19]
Stiripentol DMMSDOY Moderate Decreased metabolism of Vemurafenib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Vemurafenib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Vemurafenib and Cannabidiol. Epileptic encephalopathy [8A62] [17]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Vemurafenib caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [30]
Tazemetostat DMWP1BH Moderate Increased metabolism of Vemurafenib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [31]
Mirabegron DMS1GYT Minor Increased metabolism of Vemurafenib caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [32]
Ripretinib DM958QB Moderate Increased metabolism of Vemurafenib caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [15]
Avapritinib DMK2GZX Moderate Increased metabolism of Vemurafenib caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [17]
MK-1439 DM215WE Moderate Increased metabolism of Vemurafenib caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Vemurafenib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Dolutegravir DMCZGRE Minor Increased metabolism of Vemurafenib caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [34]
Elvitegravir DMG9B1U Moderate Increased metabolism of Vemurafenib caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Aliskiren DM1BV7W Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [19]
Lesinurad DMUR64T Moderate Increased metabolism of Vemurafenib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [18]
Berotralstat DMWA2DZ Major Decreased clearance of Vemurafenib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [35]
Suvorexant DM0E6S3 Moderate Increased metabolism of Vemurafenib caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Vemurafenib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Vemurafenib and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Naloxegol DML0B41 Minor Decreased clearance of Vemurafenib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [38]
Pemigatinib DM819JF Moderate Increased metabolism of Vemurafenib caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [17]
Brigatinib DM7W94S Moderate Increased metabolism of Vemurafenib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [15]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Vemurafenib and Ceritinib. Lung cancer [2C25] [19]
PF-06463922 DMKM7EW Moderate Increased metabolism of Vemurafenib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Vemurafenib and Osimertinib. Lung cancer [2C25] [19]
Capmatinib DMYCXKL Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [39]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Vemurafenib and Selpercatinib. Lung cancer [2C25] [19]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Vemurafenib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [40]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Vemurafenib and Idelalisib. Mature B-cell leukaemia [2A82] [41]
GDC-0199 DMH0QKA Major Decreased clearance of Vemurafenib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [15]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Vemurafenib caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [42]
Ibrutinib DMHZCPO Moderate Increased metabolism of Vemurafenib caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [43]
Ubrogepant DM749I3 Moderate Increased metabolism of Vemurafenib caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [44]
Rimegepant DMHOAUG Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Rimegepant. Migraine [8A80] [45]
Lasmiditan DMXLVDT Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [46]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Vemurafenib and Ozanimod. Multiple sclerosis [8A40] [19]
Rolapitant DM8XP26 Moderate Increased metabolism of Vemurafenib caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [47]
E-2007 DMJDYNQ Moderate Increased metabolism of Vemurafenib caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [17]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Vemurafenib and Entrectinib. Non-small cell lung cancer [2C25] [19]
Olaparib DM8QB1D Moderate Increased metabolism of Vemurafenib caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [15]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Vemurafenib and Rucaparib. Ovarian cancer [2C73] [19]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Vemurafenib and Triclabendazole. Parasitic worm infestation [1F90] [19]
Abametapir DM2RX0I Moderate Decreased metabolism of Vemurafenib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [48]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Vemurafenib and Macimorelin. Pituitary gland disorder [5A60-5A61] [49]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Vemurafenib and Lefamulin. Pneumonia [CA40] [19]
Enzalutamide DMGL19D Major Increased metabolism of Vemurafenib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [15]
Relugolix DMK7IWL Major Decreased metabolism of Vemurafenib caused by Relugolix mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [50]
Darolutamide DMV7YFT Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [51]
Selexipag DMAHSU0 Moderate Decreased metabolism of Vemurafenib caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [15]
Riociguat DMXBLMP Moderate Increased metabolism of Vemurafenib caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [52]
Tofacitinib DMBS370 Moderate Increased metabolism of Vemurafenib caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [15]
Tedizolid DMG2SKR Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [17]
LDE225 DMM9F25 Moderate Increased metabolism of Vemurafenib caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [53]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vemurafenib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [54]
Larotrectinib DM26CQR Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [15]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Vemurafenib and LEE011. Solid tumour/cancer [2A00-2F9Z] [19]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Vemurafenib and Pitolisant. Somnolence [MG42] [19]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Vemurafenib caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [18]
Fostamatinib DM6AUHV Moderate Increased metabolism of Vemurafenib caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [55]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Vemurafenib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [56]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Vemurafenib and Lenvatinib. Thyroid cancer [2D10] [19]
Linagliptin DMWFJTR Moderate Increased metabolism of Vemurafenib caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [57]
Elagolix DMB2C0E Moderate Increased metabolism of Vemurafenib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [58]
⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Vemurafenib 240 mg tablet 240 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893).
2 Zhang W, Heinzmann D, Grippo JF: Clinical Pharmacokinetics of Vemurafenib. Clin Pharmacokinet. 2017 Mar 2. doi: 10.1007/s40262-017-0523-7.
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect. 2015 Mar;3(2):e00113. doi: 10.1002/prp2.113.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
7 Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci. 2014;17(1):154-68.
8 Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43.
9 PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. J Cancer. 2015 Oct 29;6(12):1320-30. doi: 10.7150/jca.11126. eCollection 2015.
10 Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599.
11 Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity. PLoS One. 2016 Feb 1;11(2):e0148095. doi: 10.1371/journal.pone.0148095. eCollection 2016.
12 Role of the protein kinase BRAF in the pathogenesis of endometriosis. Expert Opin Ther Targets. 2016 Aug;20(8):1017-29. doi: 10.1080/14728222.2016.1180367. Epub 2016 May 4.
13 Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Sci Rep. 2016 May 25;6:26803. doi: 10.1038/srep26803.
14 HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016 May 1;76(9):2720-30. doi: 10.1158/0008-5472.CAN-15-2137. Epub 2016 Mar 16.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
19 Canadian Pharmacists Association.
20 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
21 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
22 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
24 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
25 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
26 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
27 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
28 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
29 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
30 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
31 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
32 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
33 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
34 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
35 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
36 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
37 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
38 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
39 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
40 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
41 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
42 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
44 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
45 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
46 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
47 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
48 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
50 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
51 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
52 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
53 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
55 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
56 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
57 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
58 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.